globe usa magnifying-glass checkbox g-plus rss youtube fb-round connect-with-us-in connect-with-us-twitter youtube2 facebook linkedin twitter
The website you have requested may contain information on products or uses of such products that are not approved in your country. For specific product and country information please contact Medinol

NIRxcell

Co-Cr Coronary Stent System

  • Exceptional clinical outcomes
  • Redefining deliverability with a new spring tip
  • Low footprint cobalt-chromium design
  • Optimal conformability and vessel support
Target Lesion Revascularization at 9 Months
  • Exceptionally Low TLR (Target Lesion Revascularization): 5.1% at 9 months
  • NIRxcell was tested on over 1,000 patients and found highly-effective in numerous clinical trials

Watch Dr. Kobi Richter, Founder and CTO of Medinol, discussing NIRxcell’s outstanding clinical data

  1. PIONIR Study – data from Medinol NIRxcell CoCr Coronary Stent on Rx System IFU – September 2014 (NIRxcell stent is identical to the stent used in PIONIR)
  2. OMEGA trial data from Rebel™ Platinum chromium Coronary Stent System IFU version 2014-06 EN (Boston Scientific)
  3. Multi-Link Vision Registry; Kereiakes et al., Am J Cardiol. 2003; 92:463
  4. Endeavor II Data from Medtronic Integrity Coronary Stent System IFU Rev 1A Basalus et al., Eurointervention 2013; 9:302-305